Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
OnKure Therapeutics, Inc. (OKUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: OKUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $34.2
1 Year Target Price $34.2
| 5 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -25.56% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 76.57M USD | Price to earnings Ratio 71.75 | 1Y Target Price 34.2 |
Price to earnings Ratio 71.75 | 1Y Target Price 34.2 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 1.70 - 20.00 | Updated Date 05/17/2025 |
52 Weeks Range 1.70 - 20.00 | Updated Date 05/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.08 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE 71.75 | Forward PE - | Enterprise Value 565252 | Price to Sales(TTM) - |
Enterprise Value 565252 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.57 | Shares Outstanding 12652900 | Shares Floating 4190656 |
Shares Outstanding 12652900 | Shares Floating 4190656 | ||
Percent Insiders 1.45 | Percent Institutions 96.85 |
Upturn AI SWOT
OnKure Therapeutics, Inc.
Company Overview
History and Background
OnKure Therapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines to improve the lives of patients with cancer and other diseases. While specific founding year and milestones require further research, the company is known for its work on kinase inhibitors and targeted therapies.
Core Business Areas
- Drug Discovery and Development: Focuses on identifying and developing novel therapeutic candidates for cancer and other diseases.
- Clinical Trials: Conducts clinical trials to evaluate the safety and efficacy of its drug candidates.
- Partnerships and Collaborations: Collaborates with other pharmaceutical companies and research institutions to advance its pipeline.
Leadership and Structure
Details on the leadership team and organizational structure require further investigation of publicly available sources.
Top Products and Market Share
Key Offerings
- OKI-179: A selective PI3Ku03b1 inhibitor in clinical development for solid tumors. Market share data is not publicly available. Competitors include PI3K inhibitors from larger pharmaceutical companies.
- OKI-190: A preclinical program targeting undisclosed kinases. Market share and user data is not available as it is preclinical. Competitors depend on the kinase target.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the oncology segment, is characterized by intense competition, high R&D costs, and stringent regulatory requirements. Targeted therapies and kinase inhibitors are significant growth areas.
Positioning
OnKure Therapeutics, Inc. is a smaller player in the oncology space, focused on developing innovative therapies. Its competitive advantage lies in its specific kinase inhibitor programs and targeted approach.
Total Addressable Market (TAM)
The global oncology market is estimated to be in the hundreds of billions of dollars. OnKure's TAM depends on the specific indications its drugs target and their success in clinical trials. Its current position is relatively small, but successful drug development could significantly increase its market share.
Upturn SWOT Analysis
Strengths
- Innovative kinase inhibitor programs
- Targeted therapy approach
- Experienced management team (requires verification)
- Potential for strategic partnerships
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on clinical trial success
- Limited commercial infrastructure
- Early-stage pipeline
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline through drug discovery
- Positive clinical trial results leading to regulatory approval
- Advancements in personalized medicine
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- NOVN.SW
- LLY
- AZN
Competitive Landscape
OnKure faces strong competition from larger, more established pharmaceutical companies. Its success depends on the differentiation and efficacy of its drug candidates.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is unavailable due to the company's private status.
Future Projections: Future projections are not publicly available.
Recent Initiatives: Recent initiatives are not readily available but likely involve advancing its clinical and preclinical programs.
Summary
OnKure Therapeutics is a small, private biopharmaceutical company focused on developing kinase inhibitors for cancer. Its strengths lie in its targeted therapies and potential for strategic partnerships. However, it faces challenges related to limited resources and competition from larger companies. Success hinges on positive clinical trial results and securing partnerships to advance its pipeline.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- SEC Filings (where applicable)
Disclaimers:
The information provided is based on publicly available data and should not be considered financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About OnKure Therapeutics, Inc.
Exchange NASDAQ | Headquaters Boulder, CO, United States | ||
IPO Launch date 2024-10-07 | President, CEO & Director Dr. Nicholas A. Saccomano Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 46 | Website https://onkuretherapeutics.com |
Full time employees 46 | Website https://onkuretherapeutics.com | ||
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3 kinase alpha harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company is headquartered in Boulder, Colorado.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.